Berman Capital Advisors’s Acceleron Pharma XLRN Stock Holding History

Berman Capital Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$9K	Buy	55 +9	+20%	+$1.18K	﹤0.01%	1238
2021 Q2	$5K	Sell	46 -1	-2%	-$126	﹤0.01%	1376
2021 Q1	$6K	Buy	47 +1	+2%	+$129	﹤0.01%	1245
2020 Q4	$5K	Hold	46	–	–	﹤0.01%	1190
2020 Q3	$5K	Buy	46 +12	+35%	+$1.2K	﹤0.01%	1072
2020 Q2	$3K	Hold	34	–	–	﹤0.01%	1208
2020 Q1	$3K	Buy	+34	New	+$2.64K	﹤0.01%	1085

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Berman Capital Advisors's XLRN Position: Q3 2021 in Review

Berman Capital Advisors increased its Acceleron Pharma (XLRN) stake by 20% in Q3 2021, buying an estimated $1.18K and bringing the position to 55 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1238.

Berman Capital Advisors first reported a position in XLRN in Q1 2020 and has held it in 7 quarters since. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Berman Capital Advisors held 55 shares of Acceleron Pharma worth $9K as of Q3 2021.
Berman Capital Advisors bought 9 Acceleron Pharma shares in Q3 2021, an estimated $1.18K.
Acceleron Pharma made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1238 holding.
Berman Capital Advisors first reported a position in Acceleron Pharma in Q1 2020 and has held it in 7 quarters since.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.